000			01921 a2200565 4500
005			20250515020226.0
264		0	_c20060912
008			200609s 0 0 eng d
022			_a0887-6924
024	7		_a10.1038/sj.leu.2404165 _2doi
040			_aNLM _beng _cNLM
100	1		_aMathews, V
245	0	0	_aHepatotoxicity profile of single agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia, its impact on clinical outcome and the effect of genetic polymorphisms on the incidence of hepatotoxicity. _h[electronic resource]
260			_bLeukemia _cMay 2006
300			_a881-3 p. _bdigital
500			_aPublication Type: Clinical Trial; Letter
650	0	4	_aAdult
650	0	4	_aArsenic Trioxide
650	0	4	_aArsenicals _xadministration & dosage
650	0	4	_aChemical and Drug Induced Liver Injury _xcomplications
650	0	4	_aCohort Studies
650	0	4	_aDisease-Free Survival
650	0	4	_aFemale
650	0	4	_aFollow-Up Studies
650	0	4	_aGenetic Predisposition to Disease
650	0	4	_aHumans
650	0	4	_aIncidence
650	0	4	_aLeukemia, Promyelocytic, Acute _xdiagnosis
650	0	4	_aLiver _xdrug effects
650	0	4	_aLiver Function Tests
650	0	4	_aMale
650	0	4	_aMethylenetetrahydrofolate Reductase (NADPH2) _xgenetics
650	0	4	_aOxides _xadministration & dosage
650	0	4	_aPolymorphism, Genetic
650	0	4	_aRemission Induction
650	0	4	_aRisk Factors
650	0	4	_aSurvival Rate
650	0	4	_aTreatment Outcome
700	1		_aDesire, S
700	1		_aGeorge, B
700	1		_aLakshmi, K M
700	1		_aRao, J G
700	1		_aViswabandya, A
700	1		_aBajel, A
700	1		_aSrivastava, V M
700	1		_aSrivastava, A
700	1		_aChandy, M
773	0		_tLeukemia _gvol. 20 _gno. 5 _gp. 881-3
856	4	0	_uhttps://doi.org/10.1038/sj.leu.2404165 _zAvailable from publisher's website
999			_c16134908 _d16134908